Skip to main content
TipRanks
Go Ultimate75% OFF

Medibank Private (MDBPF) AI Stock Analysis

19 Followers
MDBPF

Medibank Private

(Other OTC:MDBPF)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Steady Revenue GrowthA sustained upward revenue trajectory indicates continued demand for Medibank’s private health insurance products and services. Ongoing top-line expansion supports operating scale, provides a base for reinvestment, and can help the company absorb claims and administrative cost increases over time.
Negative Factors
Operating Profit VolatilityVariable operating profitability makes future earnings less predictable and suggests that pricing, claims, and cost cycles can materially affect results. This may limit the consistency of returns and require ongoing underwriting, pricing, and expense discipline to preserve margins through changing conditions.

Medibank Private (MDBPF) vs. SPDR S&P 500 ETF (SPY)

-20%-10%0%10%20%30%MDBPF+11.16%SPY+13.11%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$10.74B
Dividend Yield
3.72%
Average Volume (3M)
―
Price to Earnings (P/E)
23.1
Beta (1Y)
0.65
Revenue Growth
14.57%
EPS Growth
32.86%
Country
US
Employees
5,001
Sector
Financial
Sector Strength
68
Industry
Insurance - Life

Medibank Private Business Overview & Revenue Model

Company Description

Medibank Private Limited (MPL.AX) is an Australian firm offering private health insurance alongside a variety of health services. The company operates through two primary divisions. Its Health Insurance division provides a comprehensive suite of priv...

Medibank Private Earnings Call Summary

Earnings Call Date:Feb 18, 2026(Q2-2026)|% Change Since:31.99%|Next Earnings Date:Feb 24, 2027
Earnings Call SentimentPositive

The call conveyed positive operational momentum and strategic progress: group operating profit rose 6%, Medibank Health delivered strong double-digit revenue and profit growth, policyholder growth improved and the company completed a transformative primary care acquisition while maintaining a strong capital position and lifting the interim dividend. Headwinds exist—expense inflation, a revenue-mix shift toward lower-tier products, elevated claims dynamics in extras, negative hospital utilization (partly COVID-driven), lower investment income and competitive pressure from aggregators—but management presented mitigation plans, unchanged guidance ranges, and clear capacity to invest further in health businesses. Overall, the positives (earnings growth, Medibank Health acceleration, M&A scale, capital strength and customer engagement) outweigh the manageable near-term challenges.

Positive Updates

Group earnings growth
Group operating profit increased 6% to $381.7m; underlying EPS (normalizing investment returns) was $0.108 per share, broadly in line with prior year.

Negative Updates

Higher operating expenses and reinvestment
Operating expenses increased 5.4% to $329.4m; expense ratio was 7.7% (up 10bps). FY '26 expense guidance is $690m–$695m, reflecting inflation, volume impacts and continued investment (partially offset by targeted productivity savings).

Company Guidance

Medibank kept FY‑26 guidance largely unchanged: resident claims per policy unit growth of 2.6–2.9% and an expectation that 1H revenue‑mix headwind (~150bps) will be better for the full year; group operating expenses of $690–695m for FY‑26 (including $10m of productivity savings) and non‑recurring cyber/IT security costs of ~ $35m; Medibank Health organic operating profit to grow in FY‑26 broadly in line with 1H26 plus ~A$6m from the Better Medical acquisition in 2H, with a FY‑30 Medibank Health earnings aspiration of at least A$200m and capacity to raise Tier‑2 debt; capital remains strong at 1.9x PCA and a 13.8% capital ratio (above the 10–12% target while holding capital against a A$250m APRA adjustment); interim dividend A$0.083 per share (up 6.4%, 76.8% payout of underlying NPAT); underlying EPS A$0.108 and underlying net investment return 2.74% (annualized spread to RBA cash rate 184bps).

Medibank Private Peers Comparison

Overall Rating

UnderperformOutperform
Sector (68)

Financial Indicators

MDBPF against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *68Neutral$18.00B11.429.92%3.81%9.73%1.22%
AU:NHFAU:NHF64NeutralAUD 3.37B18.0316.75%4.97%5.26%-6.54%

* Financial Sector Average

Performance Comparison

-10%0%10%20%MDBPFAU:NHFDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
MDBPF and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
MDBPFMedibank Private Ltd.3.520.3511.16%
AU:NHFNIB Holdings Ltd6.84-0.04-0.64%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.